News
SNES
0.7498
-1.50%
-0.0114
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. Cyclacel Pharmaceuticals stock rose 23.04% and Compass Therapeutics shares rose 21.62%. Can Fite Biofarma (AMEX:CANF) stock also moved upwards.
Benzinga · 8h ago
Weekly Report: what happened at SNES last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at SNES last week (0408-0412)?
Weekly Report · 04/15 09:38
12 Health Care Stocks Moving In Friday's Intraday Session
PaxMedica stock increased by 110.9% to $0.87 during Friday's regular session. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% during the session. Cyclacel Pharmaceuticals shares increased by 20.45%. SenesTech and Motus GI Hldgs were among the losers.
Benzinga · 04/12 16:31
Weekly Report: what happened at SNES last week (0401-0405)?
Weekly Report · 04/08 09:40
Weekly Report: what happened at SNES last week (0325-0329)?
Weekly Report · 04/01 09:40
Weekly Report: what happened at SNES last week (0318-0322)?
Weekly Report · 03/25 09:41
Weekly Report: what happened at SNES last week (0311-0315)?
Weekly Report · 03/18 09:40
Weekly Report: what happened at SNES last week (0304-0308)?
Weekly Report · 03/11 09:39
Weekly Report: what happened at SNES last week (0226-0301)?
Weekly Report · 03/04 09:40
Weekly Report: what happened at SNES last week (0219-0223)?
Weekly Report · 02/26 09:44
12 Health Care Stocks Moving In Thursday's Intraday Session
Monopar Therapeutics shares increased by 85.9% to $1.06 during Thursday's regular session. Ocular Therapeutix stock rose 30.11%. Novavax shares rose 24.62%. Q4 earnings report came out yesterday. Losers Synaptogenix (NASDAQ:SNPX) and BioSig Technologies.
Benzinga · 02/22 17:31
SenesTech reports FY results
Seeking Alpha · 02/22 15:22
Analysts Offer Insights on Materials Companies: SenesTech (SNES) and Victoria Gold (OtherVITFF)
TipRanks · 02/22 11:22
Press Release: SenesTech Announces 2023 Financial Results
SenesTech Announces 2023 Financial Results. YTD 2024 total revenue up more than 80% compared to YTD 2023 driven by orders for Evolve(TM) soft bait. The Company is working on an enhanced form factor and dosing of a soft bait contraceptive product for mice.
Dow Jones · 02/21 21:05
Press Release: SenesTech Announces 2023 Financial -2-
Property and equipment, net: Total assets are assets minus liabilities. Equity: Common stockholders' equity. Current liabilities: Current liabilities are the sum of current assets and liabilities. Total liabilities include current portion of operating and deferred revenue. Current assets are total assets minus current liabilities. The total number of shareholders' equity is total equity.
Dow Jones · 02/21 21:05
Earnings Preview For SenesTech
SenesTech is set to give its latest quarterly earnings report on Wednesday. Analysts estimate the company will report an earnings per share of $-0.44. Last quarter the company beat EPS by $4.56, followed by a 31.27% drop in the share price. Shares of SenesTech were trading at $1.09 as of February 19.
Benzinga · 02/20 20:01
SenesTech (SNES) Expands in the Netherlands With Q-chem Deal
NASDAQ · 02/20 15:17
Weekly Report: what happened at SNES last week (0212-0216)?
Weekly Report · 02/19 09:45
12 Health Care Stocks Moving In Thursday's After-Market Session
China Pharma Holding (AMEX:CPHI) shares rose 12.7% to $0.12 during Thursday's after-market session. SenesTech (NASDAQ:SNES) shares moved upwards by 7.54%. Modular Medical stock fell 16.3% in the after-markets.
Benzinga · 02/15 21:31
More
Webull provides a variety of real-time SNES stock news. You can receive the latest news about Senestech Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNES
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.